theprior
31 May 2016
21.5p Some small buys at 21.5p just gone through. Looks promising !TP
nk1999
24 May 2016
Jefferies From Citywire:"Tissue Regenix: long-term upside in orthopaedics Orthopedics will provide long-term upside for medical device developer Tissue Regenix (TRX).Jefferies analyst Chris Cooper retained his ‘buy’ recommendation and target price of 37p on the stock after full year 2016 results. The shares were flat at 18p yesterday.‘A robust full-year 2016 with sales (£0.8 million), net loss (£0.5 million) and cash (£20 million) all broadly in line versus Jefferies estimates, marking a solid end to the year with fundamentals progressing as expected,’ he said.‘In our view the orthopaedic franchise offers the greatest long-term upside and, having completed trial enrolment in January 2016, Orthopure XM is on track for H1 2017 launch.’He added that new facilities represented a ‘significant upgrade’ and there is ‘plenty of space for capacity’.‘Our discounted cashflow indicates a fair value of 37p per share,’ said Cooper. ‘Given Tissue Regenix is still early-stage, there are few relevant comparators. Tissue Regenix operates across several product areas and has several credible products at different stages of commercialisation. We view the key risk as strategic execution. Liquidity continues to be a meaningful investment risk with only $42,000 per day traded on average.’ "
theprior
23 May 2016
Re: 23 May results Thin trading today, some brave soul has invested £100 to buy at 18p. Such confidence, astounding !! 
)The potential here is huge, a massive market is waiting for these products. I'm baffled as to why people don't see it.Just having a look for a source of funds to top up whilst the price stays this low. 18 to buy .....Bargain !!Luck all, TP
theprior
23 May 2016
23 May results Increased loss will be the main headline, but beneath this lie the increase in investment in the clinical trials and the infrastructure.Possibly a dip in sp today which will provide a good buying opportunity. (IMHO)TP
theprior
13 May 2016
23 May For unaudited prelims news release. And a presentation.Interesting !TP
theprior
25 Apr 2016
Re: RNS - Not impressed I got this response to my query about the change of Registered office"Many thanks for your enquiry.Our registered office address changed to our manufacturing facility which has been based at this address in Leeds since last year. We recently completed the last stage of this move and have now consolidated all of our UK operations to this site. Do let me know if you have any further questions. "So, another mystery solved. )No suspicious circumstances.TP
theprior
14 Apr 2016
Re: RNS - Not impressed Email sent. Will report reply (if I get one)TP
theprior
14 Apr 2016
Re: RNS - Not impressed Clearly there's a reason for the sudden move ("immediate effect" and it would be nice to know why.However, let's be clear, the registered office of a company is not the place where they work, it's often an address of convenience, for registration purposes. The change of registered office may simply to fulfil some sort of legal obligation.If I get chance I'll email them later.TP
Chicken Lips
14 Apr 2016
Re: RNS - Not impressed Bit bemused by this. I assume its the admin? But why would you want it away from the business?
ybhere
14 Apr 2016
RNS - Not impressed Today's RNS is not exactly uplifting or gives sufficient gravitas to the company. the Company's Registered Office address has changed from The Biocentre, Innovation Way, Heslington, York, YO10 5NY to: Unit 1 & 2, Astley Way, Astley Lane Industrial Estate, Swillington, Leeds LS26 8XT UNIT 1 & 2!!!. No doubt next to Arthur Daley's 2nd hand cars.YB
ybhere
22 Mar 2016
Edison Report & Analysis [link] Regenix’s (TRX’s) investment case is built on dCELL, a patented decellularised tissue scaffold. Wound care is a main driver for TRX’s growth and recent announcements demonstrate progress on many fronts. Most notably, the FDA has approved the first dCELL product as a medical device: SurgiPure XD for use in hernia repair. We have increased our sum-of-the-parts valuation to £380m (vs £346m previously).YB
theprior
21 Mar 2016
Re: What Gives? Several 100000 sells today. Someone taking profits after recent rises, maybe.Let's see what happens next, could be a chance to top up.TP
Chicken Lips
18 Mar 2016
Re: What Gives? tha
arborman
18 Mar 2016
Re: What Gives? Woodford increased their position to 17% last week, back to 30p by July IMHO, might well retrace in the meantime, but when sales figures start coming through i see this flying much higher! My target is 50pHere's the major shareholders listed on TRX investor website...Invesco Limited 27.80%Woodford Investment Management LLP 17%Techtran Group Limited 13.56%Baillie Gifford & Co Ltd 5.96%University of Leeds 4.47%Jupiter Asset Management 4.45%NFU Mutual 3.79%John Samuel 3.19%that's a whopping 80%GLA
theprior
18 Mar 2016
Re: What Gives? Yes, I guess so. Trades look mostly like PIs, there's only a couple that are serious money. So maybe just the progress in the US is the driver.This has always been a stock with huge potential so I'm looking to add more if it slips back a bit (quite likely imvho after recent rises)TP
